

# Lack of effect of adenosine on the function of rodent osteoblasts and osteoclasts in vitro

Mark O. R. Hajjawi<sup>1</sup> · Jessal J. Patel<sup>2</sup> · Michelangelo Corcelli<sup>1</sup> · Timothy R. Arnett<sup>1</sup> · Isabel R. Orriss<sup>1,2</sup>

Received: 25 September 2015 / Accepted: 1 February 2016 / Published online: 10 February 2016  
© Springer Science+Business Media Dordrecht 2016

**Abstract** Extracellular ATP, signalling through P2 receptors, exerts well-documented effects on bone cells, inhibiting mineral deposition by osteoblasts and stimulating the formation and resorptive activity of osteoclasts. The aims of this study were to determine the potential osteotropic effects of adenosine, the hydrolysis product of ATP, on primary bone cells in vitro. We determined the effect of exogenous adenosine on (1) the growth, alkaline phosphatase (TNAP) activity and bone-forming ability of osteoblasts derived from the calvariae of neonatal rats and mice and the marrow of juvenile rats and (2) the formation and resorptive activity of osteoclasts from juvenile mouse marrow. Reverse transcription polymerase chain reaction (RT-PCR) analysis showed marked differences in the expression of P1 receptors in osteoblasts from different sources. Whilst mRNA for the A<sub>1</sub> and A<sub>2B</sub> receptors was expressed by all primary osteoblasts, A<sub>2A</sub> receptor expression was limited to rat bone marrow and mouse calvarial osteoblasts and the A<sub>3</sub> receptor to rat bone marrow osteoblasts. We found that adenosine had no detectable effects on cell growth, TNAP activity or bone formation by rodent osteoblasts in vitro. The analogue 2-chloroadenosine, which is hydrolysed more slowly than adenosine, had no effects on rat or mouse calvarial osteoblasts but increased TNAP activity and bone formation by rat bone marrow osteoblasts by 30–50 % at a concentration of 1 μM. Osteoclasts were found to express

the A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors; however, neither adenosine (≤100 μM) nor 2-chloroadenosine (≤10 μM) had any effect on the formation or resorptive activity of mouse osteoclasts in vitro. These results suggest that adenosine, unlike ATP, is not a major signalling molecule in the bone.

**Keywords** Osteoblast · Osteoclast · Bone · Adenosine · 2-chloroadenosine

## Introduction

The effects of extracellular purines and pyrimidines on cell surface receptors have been extensively studied for over 40 years [1]. ATP and related compounds exert their physiological effects via seven P2X ligand-gated ion channel receptors and eight P2Y G-protein-coupled receptors that are expressed in most tissues [2, 3].

The roles played by P2X and P2Y receptors in regulating the function of bone cells have received considerable attention in recent years [4]. Osteoblasts, the bone-forming cells, express multiple P2 receptors [5, 6], in a differentiation-dependent manner [7, 8], and respond to extracellular nucleotides with a prompt increase in intracellular calcium [7–10]. Importantly, exogenous ATP, UTP and other nucleotide analogues also potently inhibit mineralisation of bone formed by osteoblasts in culture [8, 11, 12]. Moreover, endogenous ATP released by osteoblasts also appears to act as a significant local inhibitor of mineralisation [13]. The action of UTP, together with data from pharmacological studies using other selective P2 receptor agonists and antagonists indicated that P2Y<sub>2</sub>, P2X<sub>1</sub> and P2X<sub>7</sub> receptors could be involved in mediating the inhibition of mineralisation by ATP [8, 12, 13].

Osteoclasts, the bone-resorbing cells also express most P2 receptors [14] and respond to extracellular nucleotides with

✉ Timothy R. Arnett  
t.arnett@ucl.ac.uk

<sup>1</sup> Department of Cell and Developmental Biology, University College London, Anatomy Building, Gower Street, WC1E 6BT London, UK

<sup>2</sup> Department of Comparative Biomedical Sciences, Royal Veterinary College, Royal College Street, London NW1 0TU, UK

elevation of intracellular calcium [15]. Moreover, extracellular ATP, ADP and UDP have been shown to increase the formation and resorptive activity of primary rodent osteoclasts in vitro [14, 16–18]. Pharmacological evidence now suggests that the pro-resorptive action of ATP and related molecules are mediated by the P2Y<sub>1</sub>, P2Y<sub>6</sub> and P2Y<sub>12</sub> receptors [14, 17–19].

Adenosine is a hydrolysis product of ATP and is formed extracellularly by the actions of ecto-nucleotidases. There are four major families of these ecto-enzymes: (1) ecto-nucleoside triphosphate diphosphohydrolases (NTPdases), which hydrolyse ATP to ADP and finally AMP; (2) ecto-nucleotide pyrophosphatase/phosphodiesterases (NPPs) that hydrolyse ATP to AMP, with the release of pyrophosphate; (3) alkaline phosphatases, which sequentially remove single phosphate groups and can hydrolyse ATP through to adenosine; and (4) ecto-5′nucleotidase that hydrolyses AMP to adenosine. Extracellular adenosine concentrations are usually <300 nM [20] but can rise to approximately 1 μM under conditions of physiological stress [21].

The physiological actions of adenosine have been studied for over 90 years. Adenosine acts via the G-protein coupled P1-receptors, found on the surface of many cell types. The P1 receptor family can be subdivided into the A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors [22]. The A<sub>2A</sub> and A<sub>2B</sub> adenosine receptors are predominantly stimulatory and are coupled to G<sub>s</sub> to stimulate cAMP signalling; the A<sub>1</sub> and A<sub>3</sub> receptors are mainly Gi coupled and act to inhibit cAMP signalling [22].

Both osteoblasts and osteoclasts have been reported to express all four P1 receptor subtypes [23–27]. However, the actions of extracellular adenosine on bone cells appear to be somewhat less clear-cut than those of ATP. Synthetic adenosine analogues caused a receptor-mediated rise in cAMP levels in calvarial osteoblast-like cells [28], but adenosine had no effect on intracellular calcium levels in these cells [7]. Two independent groups failed to find an effect of adenosine on the formation of mineralised bone nodules by rat calvarial osteoblasts [11, 29]. However, a more recent study indicated that adenosine, acting via the A<sub>2B</sub> receptor, may increase the osteogenic differentiation of rat long bone mesenchymal stem cells [24]. In addition, a synthetic A<sub>2B</sub> receptor agonist has been shown to increase bone formation, and bone marrow osteoblasts from A<sub>2B</sub> receptor knockout mice display reduced levels of bone formation [30]. Recently, it has also been reported that stimulation of the A<sub>2A</sub> receptors can enhance bone regeneration [31].

The study of Lerner et al. (1987) found that adenosine analogues had no effect on the resorption of cultured mouse calvarial bones. Adenosine was later shown to be without effect on the formation or resorptive activity of primary rodent osteoclasts in vitro [16, 17]. Adenosine was also reported to have no effect on intracellular calcium levels in rabbit osteoclasts in vitro [32]. However, more recent work has indicated that adenosine, acting through the A<sub>2A</sub> receptor, may stimulate

the formation of osteoclasts from human peripheral blood cells [25]. In contrast, Mediero et al. (2012) [33] found that A<sub>2A</sub> receptor agonists inhibited mouse osteoclast formation in vitro. Blockade or deletion of the A<sub>1</sub> receptor has additionally been reported to reduce the formation of mouse osteoclasts in culture [23]; however, the same group also found that stimulation of the A<sub>1</sub> receptor had no effect on mouse osteoclasts [34].

The aim of the present study was to determine the direct actions of adenosine on normal osteoblasts and osteoclasts, using well-characterised assays that measure the accepted physiological functions (i.e. bone formation and bone resorption) of these cells.

## Methods

### Reagents

All tissue culture and molecular biology reagents were purchased from Life Technologies (Paisley, UK) unless stated otherwise. Chemical reagents were purchased from Sigma-Aldrich (Poole, UK). 2-chloroadenosine, GR79236, BAY606583, CGS15943 and pentostatin were purchased from Tocris (Bristol, UK). P1 receptor antibodies were obtained from Alomone (Jerusalem, Israel), the β-actin antibody from Abcam (Cambridge, UK) and HRP-conjugated secondary antibodies from Jackson Immunoresearch Laboratories (Philadelphia, USA).

### Primary bone cell culture

This study used osteoblasts from several sources namely rat/mouse calvaria and rat bone marrow. Osteoclasts were obtained from mouse bone marrow. These methods represent the most widely used and well-validated methods for obtaining primary bone cells for in vitro research.

**Rat/mouse calvarial osteoblasts** Primary cells were derived from the calvarial bones of 2–4-day-old rats (Sprague-Dawley) and mice (C57BL/6 or 129/SvTerJ). Osteoblasts were obtained using methods similar to those previously described [35–37]. Briefly, calvariae were digested using 0.25 % trypsin for 10 min, 0.2 % collagenase in Hank's buffered salt solution (HBSS) for 30 min and finally 0.2 % collagenase in HBSS for 60 min, all at 37 °C. The first two digests were discarded, and cells from the final digest were resuspended in Dulbecco's modified essential medium supplemented with 10 % foetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml amphotericin (mixture abbreviated to 'DMEM'). Due to increased nutritional requirements [36], mouse cells were resuspended in α-modified essential medium supplemented with 10 % foetal

calf serum, 70 µg/ml gentamicin, 50 U/ml penicillin, 50 µg/ml streptomycin, and 0.125 µg/ml amphotericin (mixture abbreviated to 'α-MEM').

Osteoblasts were cultured for 4 days in 75 cm<sup>2</sup> flasks in a 5 % CO<sub>2</sub> atmosphere at 37 °C until confluent. Upon confluence, rat cells were then plated into six-well trays in DMEM further supplemented with 2 mM β-glycerophosphate, 50 µg/ml ascorbate and 10 nM dexamethasone (mixture abbreviated to 'supplemented DMEM') [35–37]. Mouse cells were plated into six-well trays in α-MEM further supplemented with 2 mM β-glycerophosphate and 50 µg/ml ascorbate (mixture abbreviated to 'supplemented α-MEM'). Osteoblasts were treated with 1nM–100 µM adenosine, 2-chloroadenosine, GR79235 (selective A<sub>1</sub> receptor agonist), BAY606583 (a selective A<sub>2B</sub> receptor agonist), CGS15943 (a non-selective P1 receptor antagonist), pentostatin (an adenosine deaminase inhibitor), ATP or phosphate-buffered saline (PBS) (vehicle) for the duration of the culture. Half-medium changes were performed every third day of culture. Experiments were terminated by fixing the cells in 2.5 % glutaraldehyde for 5 min. Cell culture plates were imaged at 800 dpi using a flat-bed scanner (Epson Perfection 4990 Photo), and the total area of bone nodules formed was quantified by image analysis, as described previously [35–37].

**Rat bone marrow osteoblasts** Primary rat osteoblasts of bone marrow/stromal cell origin were obtained from the long bones of 6-week-old Sprague-Dawley rats. The epiphyses were cut across and the marrow was flushed out of the bones using PBS. The collected cells were suspended in α-MEM and pre-cultured in a 75 cm<sup>2</sup> flask in 5 % CO<sub>2</sub> at 37 °C. After 24 h, all the α-MEM was replaced in order to eliminate non-adherent cells; adherent stromal cells were cultured for a further 2 days until confluent. Upon confluence, cells were plated into six-well trays and cultured as described above.

**Mouse osteoclasts** Osteoclasts were formed from precursors flushed from the bone marrow of 8-week-old mice using previously described methods [38]. Cells were pre-incubated in a 75 cm<sup>2</sup> flask containing modified essential medium supplemented with 10 % FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin and 100 nM prostaglandin E<sub>2</sub> (abbreviated as 'MEM'), supplemented with 2.5 ng/ml macrophage colony stimulating factor (M-CSF; R&D Abingdon, UK) in 5 % CO<sub>2</sub> at 37 °C. After 24 h, the non-adherent mononuclear cells remaining in the culture medium were collected. The cells were resuspended in MEM supplemented with 10 ng/ml M-CSF and 3 ng/ml receptor activator of NF-κB (RANKL) (R&D Abingdon, UK) and seeded onto 5-mm-diameter ivory discs in a 96-well tray (10<sup>6</sup> cells/disc). After a further 24 h, the ivory discs were transferred into six-well trays and cultured for 6 days at pH 7.30. Discs were cultured for the final 2 days in a medium

acidified to pH 6.90 to activate osteoclastic resorption [38] before fixation in 2.5 % glutaraldehyde and staining to demonstrate tartrate-resistant acid phosphatase (TRAP). Osteoclasts were identified as TRAP-positive cells with ≥2 nuclei. The numbers of osteoclasts and area resorbed per disc were evaluated 'blind' using transmitted and reflected light microscopy, as described previously [38].

### Alkaline phosphatase activity

Osteoblast tissue non-specific alkaline phosphatase (TNAP) activity was measured in cell lysates taken at defined stages of osteoblast differentiation (proliferating, differentiating, mature, mature bone-forming) using a colorimetric kit (Anaspec, CA, USA), as previously described [35]. TNAP activity was normalised to cell protein using the Bradford reagent (Sigma-Aldrich, Poole, UK).

### Cell number and viability assays

Osteoblast cell number was measured at regular intervals throughout the culture period using a commercially available kit (CytoTox 96, Promega UK, Southampton, UK), as previously described [13]. This assay measures the activity of lactate dehydrogenase (LDH), a cytosolic enzyme which is released on cell lysis.

### RNA extraction and RT-PCR

Osteoblasts were cultured in six-well trays for up to 28 days, and total RNA was extracted using TRIzol reagent, according to the manufacturer's instructions. Osteoclasts were cultured on 1-cm-diameter dentine discs for up to 10 days before RNA extraction. RNA was treated with RNase-free DNase I (Promega UK, Southampton, UK) for 30 min at 37 °C to remove contaminating genomic DNA. The reaction was terminated by heat inactivation at 65 °C for 10 min. Total RNA was quantified spectrophotometrically by measuring absorbance at 260 nm. Complementary DNA (cDNA) was synthesised from approximately 1 µg of RNA using Superscript III reverse transcriptase, oligo dT, RNasin and a deoxyribo-nucleotide mix.

The cDNA produced from osteoblast and osteoclast RNA was amplified by PCR using 1 U GoTaq DNA polymerase, 1.5 mM MgCl<sub>2</sub>, 0.8 µM nucleotide mix (Promega UK, Southampton, UK) and 0.5 µM primers (MWG Biotech, Ebersberg, Germany). The primer sequences used for rat and mouse reverse transcription polymerase chain reaction (RT-PCR) are shown in Table 1.

### Western blot

Protein was extracted from mature rat calvarial osteoblasts and osteoclasts. Cell layers were lysed in ice-cold radio

**Table 1** Primer sequences used for RT-PCR analysis of rodent P1 receptor mRNA expression

	Sense	Anti-sense
Rat primer 5'–3'		
A <sub>1</sub> receptor	CTCCATTCTGGCTCTGCTCG	CTCCATTCTGGCTCTGCTCG
A <sub>2A</sub> receptor	CCATGCTGGGCTGGAACA	GAAGGGGCAGTAACACGAACG
A <sub>2B</sub> receptor	TGGCGCTGGAGCTGGTTA	GCAAAGGGGATGGCGAAG
A <sub>3</sub> receptor	AGAGCTAGGTCCACTGGC	GCACATGACAACCAGGGGGATGA
β-actin	GTTCCGCATGGATGACGAT	TCTGGGTCATCTTTTCACGG
Mouse primer 5'–3'		
A <sub>1</sub> receptor	CTACCTTCTGCTTCATCGTA	ACAAGACAGTGGTGACTCAG
A <sub>2A</sub> receptor	CTATTGCCATCGACAGATAC	GAACAACCTGCAGTCAGAAAG
A <sub>2B</sub> receptor	CCACCAACTACTTTCTGGTA	AACAGTAAAGACAGTGCCAC
A <sub>3</sub> receptor	TCATTGTCTCCCTAGCACT	GACARCRRRCARCARCCG
GAPDH	CTCACTCAAGATTGTCAGCA	GTCATCATACTTGGCAGGTT

*GAPDH* glyceraldehyde-3-phosphate dehydrogenase

immunoprecipitation (RIPA) lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1 % SDS 1 mM phenyl methyl sulfonyl fluoride (PMSF), 1 mg/ml aprotinin, 1 mM Na<sub>3</sub>VO<sub>4</sub> and 2.5 mg/ml deoxycholic acid). Cell homogenates were sonicated for 5 min and stored at –80 °C for at least half an hour before use. Protein concentrations from lysates were determined using the Bradford assay (Sigma-Aldrich, Gillingham, Dorset, UK). Prior to loading, total protein samples were denatured by incubating at 95 °C for 5 min in the presence of 5× reducing sample buffer (60 mM Tris-HCl pH 6.8, 25 % glycerol, 2 % SDS, 10 % β-mercaptoethanol and 0.1 % bromophenol blue). Protein samples (20 μg/lane) were loaded into SDS-PAGE (10 %) gels and transferred onto a polyvinylidene difluoride (PVDF) membrane (Amersham, Buckinghamshire, UK) by the use of a wet tank blotter (Bio-Rad, Hercules, CA, USA) at 150 V for 1 h. Membranes were then blocked with 5 % non-fat milk and incubated with one of the P1 receptor antibodies (1:200) or β-actin (1:1000) overnight at room temperature. After washing, blots were incubated in horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature (1:10,000). A peroxidase detection system (Immobilon™ Western, Millipore UK, Watford, UK) was used for the visualisation of the immunoreactivity.

### Statistics

Statistical comparisons were made using one-way analysis of variance (ANOVA) and adjusted for multiple comparisons using the Bonferroni method. Calculations were performed using In Stat 3 (GraphPad, San Diego, CA). All data are presented as means ± SEM for 6–12 biological replicates. Results are representative of experiments performed at least three times, using cells from different animals.

## Results

### Rodent osteoblasts and osteoclasts express P1 receptor mRNA in vitro

Total RNA was extracted from mature, bone-forming osteoblasts derived from rat calvaria (day 14), rat bone marrow (day 17) and mouse calvaria (day 28). RT-PCR showed messenger RNA (mRNA) expression of the A<sub>1</sub> and A<sub>2B</sub> receptors in rat calvarial osteoblasts and all P1 receptors in rat bone marrow osteoblasts (Fig. 1a). Mouse calvarial osteoblasts expressed mRNA for A<sub>1</sub>, A<sub>2A</sub> and A<sub>2B</sub> receptors but not the A<sub>3</sub> receptor (Fig. 1a).


RNA was extracted from mature, resorbing osteoclasts (day 10 of culture) for investigation of P1 receptor expression. Osteoclasts were found to express mRNA for the A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub> receptors (Fig. 1a).

Total protein was extracted from mature rat calvarial osteoblasts and mouse osteoclasts. Western blot analysis revealed expression of A<sub>2A</sub> and A<sub>2B</sub> receptor protein in osteoblasts; A<sub>1</sub> and A<sub>3</sub> receptor protein was not detected (Fig. 1b). Osteoclasts were found to express protein for all four adenosine receptors (Fig. 1b).

### The effects of P1 receptor agonists on bone formation

Rodent calvarial osteoblasts and rat bone marrow osteoblasts were cultured for up to 28 days with adenosine, 2-chloroadenosine and ATP. Rat calvarial osteoblasts were also additionally treated with the more selective agonists, GR79236 (A<sub>1</sub>) and BAY606583 (A<sub>2B</sub>). Representative light microscopy images of adenosine and 2-chloroadenosine-treated cell layers are shown in Fig. 2. In cultures of calvarial and bone marrow osteoblasts, adenosine had no effect on the level of bone formation (Fig. 3a–c). 2-chloroadenosine was without effect in calvarial osteoblasts (Fig. 3d, e) but caused a

**Fig. 1** Expression of P1 receptors by rodent bone cells. **a** Rat calvarial osteoblasts expressed  $A_1$  and  $A_{2B}$  receptor mRNA whilst rat bone marrow osteoblasts showed expression of all four adenosine receptors. Mouse calvarial osteoblasts expressed the  $A_1$ ,  $A_{2A}$  and  $A_{2B}$  receptors. Mouse osteoclasts expressed mRNA for the  $A_{2A}$ ,  $A_{2B}$  and  $A_3$  receptors. Positive control: rat/mouse brain. **b** Western blot analysis showed that rat calvarial osteoblasts expressed low levels of  $A_{2A}$  and  $A_{2B}$  receptor proteins. Mouse osteoclasts expressed protein for all four of the adenosine receptors. Images are representative of experiments performed using mRNA and protein from three separate cell populations




small stimulatory effect at  $1 \mu\text{M}$  in bone marrow osteoblasts (Fig. 3f). Concentrations of  $\geq 10 \mu\text{M}$  2-chloroadenosine appeared to have toxic effects, resulting in a complete abolition of bone formation. ATP ( $\geq 10 \mu\text{M}$ ) inhibited mineralisation by  $\leq 90$  and  $\leq 85$  % in calvarial and bone marrow osteoblasts, respectively (Fig. 3g–i). Treatment with GR79236 and BAY606583 also had no effect on bone formation by osteoblasts (Fig. 4a, b).


### Endogenous adenosine does not affect bone formation

Rat osteoblasts were cultured with CGS15943, a non-selective P1 receptor antagonist, and pentostatin, an adenosine deaminase inhibitor, to determine whether endogenous adenosine influences bone formation. Both CGS15943 and pentostatin ( $\leq 1 \mu\text{M}$ ) had no effect on the level of bone formation (Fig. 4c, d).

**Fig. 2** Effects of adenosine and 2-chloroadenosine on mineralised bone nodule formation by rodent osteoblasts. Representative images ( $n = 5$ ) showing alizarin red-stained mineralised bone nodules, viewed by phase contrast microscopy (left) and low power reflected light scans (right). Adenosine ( $\leq 100 \mu\text{M}$ ) had no effect on bone formation by rat calvarial, mouse calvarial or rat bone marrow osteoblasts (cultured on plastic for 14, 28 and 17 days, respectively). 2-chloroadenosine ( $1 \mu\text{M}$ ) caused a modest increase in bone formation by rat bone marrow osteoblasts only. Scale bars: left, 1 mm; right, 1 cm




**Fig. 3** Effects of adenosine, 2-chloroadenosine and ATP on mineralised bone nodule formation by cultured rodent osteoblasts. Adenosine had no effect on mineralised nodule formation in cultures of **a** rat calvarial, **b** mouse calvarial or **c** rat bone marrow osteoblasts. 2-chloroadenosine was also without effect in **d** rat calvarial or **e** mouse calvarial osteoblasts but caused **f** a ~50 % increase in nodule formation by rat bone marrow osteoblasts (1  $\mu$ M only). The complete abolition of bone formation at concentrations of **e**, **f** 10  $\mu$ M and **d** 100  $\mu$ M 2-chloroadenosine suggests toxicity at these levels. ATP inhibited bone formation by **g** rat calvarial, **h** mouse calvarial and **i** rat bone marrow osteoblasts by up to 90 %. Data are means  $\pm$  SEM for six replicate determinations,  $n=5$ ; \* $p<0.05$ ; \*\* $p<0.01$ ; \*\*\* $p<0.001$



### Increased TNAP activity in bone marrow osteoblasts treated with 2-chloroadenosine

The effect of adenosine and 2-chloroadenosine on TNAP activity was measured in calvarial and long bone osteoblasts at different stages of differentiation (proliferating, differentiating, mature, mature bone-forming).

Adenosine had no effect on TNAP activity (Fig. 5a–c). 2-chloroadenosine (1  $\mu$ M) was without effect in calvarial osteoblasts (Fig. 5d, e) but increased TNAP activity by  $\leq 48$  % in rat bone marrow osteoblasts (Fig. 5f). This effect was evident in differentiating (day 11), mature (day 14) and mature, bone-forming (day 17) osteoblasts.



**Fig. 4** The effects of selective adenosine receptor agonists and endogenous adenosine on bone formation by osteoblasts. At concentrations up to 10  $\mu\text{M}$  the selective  $A_1$  agonist, GR79236, and  $A_{2B}$  agonist, BAY606583 did not affect mineralised bone nodule formation by rat calvarial osteoblasts. **c** The non-selective adenosine receptor antagonist, CG15943, and **d** the adenosine deaminase inhibitor, pentostatin, also had no effect on the level of bone formation. Data are means  $\pm$  SEM for six replicate determinations ( $n=3$ )

#### Osteoblast numbers are unaffected by adenosine or 2-chloroadenosine

Calvarial and long bone marrow osteoblasts were cultured for up to 28 days with adenosine or 2-chloroadenosine; cell numbers were estimated at the different stages of osteoblast differentiation using a lactate dehydrogenase assay. Adenosine had no effect on calvarial or long bone osteoblast numbers at any time point at concentrations up to 100  $\mu\text{M}$  (Fig. 6a–c). 2-chloroadenosine did not influence cell number in cultures of rat calvarial osteoblasts at concentrations up to 10  $\mu\text{M}$  (Fig. 6d). In mouse calvarial and rat long bone osteoblasts,  $\leq 1$   $\mu\text{M}$  2-chloroadenosine had no effect on cell number but 10  $\mu\text{M}$  2-chloroadenosine was toxic, resulting in widespread cell death (Fig. 6e, f).

#### Lack of effect of adenosine or 2-chloroadenosine on osteoclast formation and resorptive activity

The effect of adenosine, 2-chloroadenosine and ATP was examined in cultures of mouse osteoclasts cultured on ivory discs. Representative light microscopy images of treated osteoclasts are shown in Fig. 7a. At all the concentrations tested, adenosine (Fig. 7b, e) and 2-chloroadenosine (Fig. 7c, f) had no effect on osteoclast number or the amount of resorption per osteoclast. In contrast, ATP increased osteoclast formation up to  $\leq 75\%$  and bone resorption by up to twofold (Fig. 7d, g).


#### Discussion

The role of adenosine in the regulation of bone cell function has been a significant area of study (see review [39]) yet published data present conflicting results. The aim of this investigation was to clarify the functional effects of adenosine on osteoblasts and osteoclasts. We found that adenosine and the selective  $P_1$  receptor agonists, GR79236 ( $A_1$ ) and BAY606583 ( $A_{2B}$ ), had no effect on osteoblast number and/or bone formation. However, 2-chloroadenosine (a synthetic, universal  $P_1$  receptor agonist) modestly increased TNAP activity and bone formation by rat bone marrow osteoblasts but did not affect rat and mouse calvarial osteoblasts. Osteoclast formation and activity was also unaffected by adenosine or 2-chloroadenosine. In contrast, the established osteogenic inhibitory effects [12] and osteoclastic stimulatory effects [17] of ATP were readily observed in all cells.

The work presented here showed no effects of adenosine, 2-chloroadenosine, GR79236 or BAY606583 on calvarial-derived osteoblasts; this is in broad agreement with previous studies which showed exogenous adenosine had no effect on cultured rat osteoblasts [11, 29]. However, our results are at variance with several studies which found that adenosine or adenosine analogues, acting via the  $A_{2A}$  or  $A_{2B}$  receptors, stimulate the differentiation and function of human and rodent bone marrow osteoblasts and promote bone regeneration [24, 30, 31, 40]. Our data also do not concur with the reported inhibitory effects of adenosine analogues, acting via  $A_1$  or  $A_{2A}$  receptors, on the differentiation of rodent osteoblast-like cells [41] or human osteoblasts [40]. We did observe small stimulatory effects of 2-chloroadenosine on rat bone marrow osteoblasts. This synthetic agonist is more potent than adenosine and is hydrolysed more slowly [42]. Differences in agonist pharmacology may therefore explain why we observed small effects with this analogue, but adenosine was inactive in bone marrow osteoblasts.

It is possible that significant differences in osteoblast culture methodologies also contributed to the divergent results between studies. Bone formation in vitro can be influenced

**Fig. 5** Effects of adenosine and 2-chloroadenosine on alkaline phosphatase (TNAP) activity of rodent osteoblasts. Culture with adenosine had no effect on TNAP activity in **a** rat calvarial, **b** mouse calvarial and **c** rat bone marrow osteoblasts at any stage of culture. 2-chloroadenosine had no effect on TNAP activity in **d** rat and **e** mouse calvarial osteoblasts but **f** increased TNAP activity by up to 48 % in rat bone marrow osteoblasts. Data are means  $\pm$  SEM for six replicate determinations ( $n=3-5$ ): \* $p<0.05$ , \*\* $p<0.01$



by a number of variables including use of glucocorticoids (which are strongly osteogenic for rat but not mouse-derived cells *in vitro* [36, 43]) in the culture medium, culture duration, cell seeding densities, tissue culture medium,  $\beta$ -glycerophosphate concentration and the age of the animals from which the cells were isolated.


The breakdown of ATP released by cells represents a key source of extracellular adenosine. Osteoblasts release ATP constitutively [44, 45] and can generate low micromolar concentrations of adenosine *in vitro* [21, 27]. Therefore, the possibility remains that endogenous adenosine exerts effects on osteoblasts that are not enhanced further by the addition of exogenous adenosine. To investigate this possibility further, rat osteoblasts were cultured with a non-selective P1 receptor antagonist, CGS15943, to block all adenosine-mediated signalling. Cells were also cultured with pentostatin which inhibits adenosine deaminase and prevents adenosine breakdown to inosine. Both CGS15943 and pentostatin had no effect on the level of bone formation *in vitro*. Taken together, this suggests that signalling mediated by endogenous adenosine does not exert a significant effect on calvarial osteoblast function.

Earlier work has shown that osteoblasts express all the adenosine receptors [24, 27]. The present study examined the expression profile of P1 receptors in mature, bone-forming osteoblasts from different sources. In agreement with the previous studies, rat bone marrow expressed low levels of mRNA for all four receptors. However, calvarial osteoblasts displayed more restricted expression at both the protein and mRNA level. Osteoblasts expressed mRNA for the  $A_1$  receptor yet no protein was detected, suggesting this receptor is not translated. In contrast, we found that osteoblasts expressed  $A_{2A}$  receptor protein but not mRNA. This discrepancy suggests that expression of  $A_{2A}$  receptor mRNA is below the threshold that can be detected by conventional PCR. The limited adenosine receptor expression on calvarial osteoblasts may also contribute to the lack of functional effects seen in these cells.

Previous work reported that P1 receptor expression by human and rat bone marrow mesenchymal stem cells and osteoblasts is strongly dependent on differentiation [24, 40], as is P2 receptor expression by rat calvarial osteoblasts [7]. Although not investigated here, it is possible that P1 receptor expression in osteoblasts is also affected by differentiation.



**Fig. 6** Osteoblast numbers are unaffected by adenosine and 2-chloroadenosine. Treatment with adenosine had no effect on cell number in cultures of **a** rat calvarial, **b** mouse calvarial and **c** rat bone marrow osteoblasts at any stage. 2-chloroadenosine ( $\leq 1 \mu\text{M}$ ) was also without effect in **d** rat calvarial, **e** mouse calvarial and **f** bone marrow osteoblasts. 0 indicates that there were no viable cells present suggesting toxicity at concentrations of  $\geq 10 \mu\text{M}$  2-chloroadenosine. Data are means  $\pm$  SEM for six replicate determinations ( $n = 3\text{--}5$ )




Several studies have shown that  $A_1$  receptors and  $A_{2A}$  receptors can form homomers [46, 47] or  $A_1$ - $A_{2A}$  heteromers [48].  $A_1$ -P2Y<sub>1</sub> and  $A_1$ -P2Y<sub>2</sub> adenosine-receptor-ATP-receptor G-protein heteromers have also been reported [49, 50]. This receptor dimerisation may lead to alterations in downstream signalling and cellular responses to P1 receptor agonists, potentially contributing to the different effects observed between cell types.

Available data regarding the effects of adenosine and P1 receptors on osteoclasts are also conflicting. Consistent with earlier studies, we showed that osteoclasts express all four adenosine receptors, albeit at a low level [23, 25]. However, we demonstrated that adenosine had no effect on the formation or resorptive activity of mouse osteoclasts grown on dentine. These results are in agreement with some previous investigations [16, 17] but differ from others. For example,  $A_{2A}$  receptor agonists have been shown to both inhibit [33] and stimulate [25] the formation and activity of osteoclasts. Kara and colleagues [51] found that  $A_1$  receptor antagonists decreased osteoclast formation and resorption. However, we found that mouse

osteoclasts only express low levels of  $A_1$  receptor protein. Pellegatti et al. [25] also reported that the  $A_1$  receptor was only weakly expressed by osteoclasts formed from human peripheral blood. Taken together, this suggests that the  $A_1$  receptor is unlikely to play a role in regulating osteoclast function. It should be noted that the culture conditions used by the above studies varied considerably. Osteoclast formation and activity is strongly influenced by factors including RANKL/M-CSF concentration, substrate (dentine, bone or plastic), pH, source of cells and culture duration [38]. Thus, different experimental conditions combined with variations in P1 receptor expression may account for the disparity between studies.

The lack of effect of adenosine on osteoblasts and osteoclasts in this study suggests that the P1 receptors are not critical in regulating bone cell function directly. However,  $A_1$  and  $A_{2B}$  receptor knockout mice are reported to display increases in the trabecular and/or cortical bone [23, 30], whilst  $A_{2A}$  receptor knockout mice have decreased cortical and trabecular bone [33]. At

**Fig. 7** Lack of effect of adenosine and 2-chloroadenosine on the formation and resorptive activity of mouse osteoclasts. Osteoclasts were generated in 10-day cultures of mouse marrow cells on ivory discs, in the presence or absence of adenosine, 2-chloroadenosine or ATP. Cells were acidified to pH 6.90 on day 8 of culture to activate resorption. **a** Representative transmitted light images of cultures, showing tartrate-resistant acid phosphatase-positive multinucleated osteoclasts (*large red cells*) and resorption pits (*tan areas*); scale bar = 50  $\mu\text{m}$ . **b, e** Adenosine and **c, f** 2-chloroadenosine were without effect on osteoclast formation and resorptive activity. **d, g** ATP increased osteoclast formation by  $\leq 75\%$  and resorption by twofold. Data are means  $\pm$  SEM for eight replicate determinations ( $n = 3$ ); \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$



present, the  $A_3$  receptor knockout has not been investigated for specific changes in the bone; however, no overt changes in phenotype have been noted [52]. Adenosine receptors display widespread expression and are involved in many biological processes including coronary vasodilation [53], VEGF production, angiogenesis [54, 55] and nerve transmission [56]. Thus, it is possible that the changes in bone mass seen in the knockout mouse models are occurring indirectly via actions on other tissues.

In summary, this study used established and well-validated assays for measuring accepted bone cell function. We clearly show that supraphysiological concentrations of adenosine did not affect rodent osteoblasts or mouse osteoclasts. In rat bone marrow osteoblasts, 2-chloroadenosine exerted small effects on TNAP activity and bone formation but only when added to cell cultures in extremely high concentrations. 2-chloroadenosine was without effect on the other cell

types used. We also provide evidence to suggest endogenous adenosine does not influence bone formation. Taken together these data suggests that adenosine has very little direct effect on osteoblast and osteoclast function.

**Acknowledgments** The authors are grateful for the funding from Arthritis Research UK (Career Development Fellowship, 19205, IRO).

## References

1. Burnstock G (1972) Purinergic nerves. *Pharmacol Rev* 24:509–581
2. Abbracchio MP, Burnstock G (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? *Pharmacol Ther* 64:445–475
3. Burnstock G (2007) Purine and pyrimidine receptors. *Cell Mol Life Sci* 64:1471–1483
4. Burnstock G, Arnett TR, Orriss IR (2013) Purinergic signalling in the musculoskeletal system. *Purinergic Signal* 9:541–572

5. Hoebertz A, Townsend-Nicholson A, Glass R, Burnstock G, Arnett TR (2000) Expression of P2 receptors in bone and cultured bone cells. *Bone* 27:503–510
6. Bowler WB, Buckley KA, Gartland A, Hipskind RA, Bilbe G, Gallagher JA (2001) Extracellular nucleotide signaling: a mechanism for integrating local and systemic responses in the activation of bone remodeling. *Bone* 28:507–512
7. Orriss IR, Knight GE, Ranasinghe S, Burnstock G, Arnett TR (2006) Osteoblast responses to nucleotides increase during differentiation. *Bone* 39:300–309
8. Orriss IR, Key ML, Brandao-Burch A, Patel JJ, Burnstock G, Arnett TR (2012) The regulation of osteoblast function and bone mineralisation by extracellular nucleotides: the role of P2X receptors. *Bone* 51:389–400
9. Kumagai H, Sakamoto H, Guggino S, Filburn CR, Sacktor B (1989) Neurotransmitter regulation of cytosolic calcium in osteoblast-like bone cells. *Calcif Tissue Int* 45:251–254
10. Schofl C, Cuthbertson KS, Walsh CA, Mayne C, Cobbold P, von zur MA, Hesch RD, Gallagher JA (1992) Evidence for P2-purinoreceptors on human osteoblast-like cells. *J Bone Miner Res* 7:485–491
11. Hoebertz A, Mahendran S, Burnstock G, Arnett TR (2002) ATP and UTP at low concentrations strongly inhibit bone formation by osteoblasts: a novel role for the P2Y<sub>2</sub> receptor in bone remodeling. *J Cell Biochem* 86:413–419
12. Orriss IR, Utting JC, Brandao-Burch A, Colston K, Grubb BR, Burnstock G, Arnett TR (2007) Extracellular nucleotides block bone mineralization in vitro: evidence for dual inhibitory mechanisms involving both P2Y<sub>2</sub> receptors and pyrophosphate. *Endocrinology* 148:4208–4216
13. Orriss IR, Key ML, Hajjawi MO, Arnett TR (2013) Extracellular ATP released by osteoblasts is a key local inhibitor of bone mineralisation. *PLoS One* 8:e69057
14. Orriss IR, Wang N, Burnstock G, Arnett TR, Gartland A, Robaye B, Boeynaems JM (2011) The P2Y<sub>6</sub> receptor stimulates bone resorption by osteoclasts. *Endocrinology* 152:3706–3716
15. Reyes JP, Sims SM, Dixon SJ (2011) P2 receptor expression, signaling and function in osteoclasts. *Front Biosci (Schol Ed)* 3:1101–1118
16. Morrison MS, Turin L, King BF, Burnstock G, Arnett TR (1998) ATP is a potent stimulator of the activation and formation of rodent osteoclasts. *J Physiol* 511:495–500
17. Hoebertz A, Meghji S, Burnstock G, Arnett TR (2001) Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y<sub>1</sub> receptor on bone cells. *FASEB J* 15:1139–1148
18. Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN (2012) The ADP receptor P2RY<sub>12</sub> regulates osteoclast function and pathologic bone remodeling. *J Clin Invest* 122:3579–3592
19. Syberg S, Brandao-Burch A, Patel JJ, Hajjawi M, Arnett TR, Schwarz P, Jorgensen NR, Orriss IR (2012) Clopidogrel (Plavix(R)), a P2Y<sub>12</sub> receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. *J Bone Miner Res* 27:2373–2386
20. Martin C, Leone M, Viviand X, Ayem ML, Guieu R (2000) High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. *Crit Care Med* 28:3198–3202
21. Fredholm BB, Sollevi A (1981) The release of adenosine and inosine from canine subcutaneous adipose tissue by nerve stimulation and noradrenaline. *J Physiol* 313:351–367
22. Fredholm BB APIJ, Jacobson KA, Linden J, Muller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. *Pharmacol Rev* 63:1–34
23. Kara FM, Doty SB, Boskey A, Goldring S, Zaidi M, Fredholm BB, Cronstein BN (2010) Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. *Arthritis Rheum* 62:534–541
24. Gharibi B, Abraham AA, Ham J, Evans BA (2011) Adenosine receptor subtype expression and activation influence the differentiation of mesenchymal stem cells to osteoblasts and adipocytes. *J Bone Miner Res* 26:2112–2124
25. Pellegatti P, Falzoni S, Donvito G, Lemaire I, Di Virgilio F (2011) P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. *FASEB J* 25:1264–1274
26. Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R, Goldring MB, Borea PA, Varani K (2013) Pulsed electromagnetic fields increased the anti-inflammatory effect of A(2)A and A(3) adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts. *PLoS One* 8:e65561
27. Evans BA, Elford C, Pexa A, Francis K, Hughes AC, Deussen A, Ham J (2006) Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin. *J Bone Miner Res* 21:228–236
28. Lerner UH, Sahlberg K, Fredholm BB (1987) Characterization of adenosine receptors in bone. Studies on the effect of adenosine analogues on cyclic AMP formation and bone resorption in cultured mouse calvaria. *Acta Physiol Scand* 131:287–296
29. Jones SJ, Gray C, Boyde A, Burnstock G (1997) Purinergic transmitters inhibit bone formation by cultured osteoblasts. *Bone* 21:393–399
30. Carroll SH, Wigner NA, Kulkarni N, Johnston-Cox H, Gerstenfeld LC, Ravid K (2012) A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. *J Biol Chem* 287:15718–15727
31. Mediero A, Wilder T, Perez-Aso M, Cronstein BN (2015) Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2. *FASEB J* 29:1577–1590
32. Korcok J, Raimundo LN, Ke HZ, Sims SM, Dixon SJ (2004) Extracellular nucleotides act through P2X7 receptors to activate NF-kappaB in osteoclasts. *J Bone Miner Res* 19:642–651
33. Mediero A, Kara FM, Wilder T, Cronstein BN (2012) Adenosine A(2A) receptor ligation inhibits osteoclast formation. *Am J Pathol* 180:775–786
34. He W, Cronstein BN (2012) Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling. *Purinergic Signal* 8:327–337
35. Orriss IR, Taylor SE, Arnett TR (2012) Rat osteoblast cultures. *Methods Mol Biol* 816:31–41
36. Orriss IR, Hajjawi MO, Huesa C, MacRae VE, Arnett TR (2014) Optimisation of the differing conditions required for bone formation in vitro by primary osteoblasts from mice and rats. *Int J Mol Med* 3:1201–1208
37. Taylor SE, Shah M, Orriss IR (2014) Generation of rodent and human osteoblasts. *BoneKEy Rep* 3:585
38. Orriss IR, Arnett TR (2012) Rodent osteoclast cultures. *Methods Mol Biol* 816:103–117
39. Evans BA (2012) Does adenosine play a role in bone formation, resorption and repair? *Purinergic Signal* 8:177–180
40. Costa MA, Barbosa A, Neto E, Sa-e-Sousa A, Freitas R, Neves JM, Magalhaes-Cardoso T, Ferreirinha F, Correia-de-Sa P (2011) On the role of subtype selective adenosine receptor agonists during proliferation and osteogenic differentiation of human primary bone marrow stromal cells. *J Cell Physiol* 226:1353–1366

41. Gharibi B, Abraham AA, Ham J, Evans BA (2012) Contrasting effects of A1 and A2b adenosine receptors on adipogenesis. *Int J Obes* 36:397–406
42. Daly JW, Padgett WL, Secunda SI, Thompson RD, Olsson RA (1993) Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. *Pharmacology* 46:91–100
43. Bellows CG, Wang YH, Heersche JN, Aubin JE (1994) 1,25-dihydroxyvitamin D3 stimulates adipocyte differentiation in cultures of fetal rat calvaria cells: comparison with the effects of dexamethasone. *Endocrinology* 134:2221–2229
44. Orriss IR, Knight GE, Utting JC, Taylor SE, Burnstock G, Arnett TR (2009) Hypoxia stimulates vesicular ATP release from rat osteoblasts. *J Cell Physiol* 220:155–162. doi:10.1002/jcp.21745
45. Genetos DC, Geist DJ, Liu D, Donahue HJ, Duncan RL (2005) Fluid shear-induced ATP secretion mediates prostaglandin release in MC3T3-E1 osteoblasts. *J Bone Miner Res* 20(1):41–49
46. Ciruela F, Casado V, Mallol J, Canela EI, Lluís C, Franco R (1995) Immunological identification of A1 adenosine receptors in brain cortex. *J Neurosci Res* 42:818–828
47. Canals M, Burgueno J, Marcellino D, Cabello N, Canela EI, Mallol J, Agnati L, Ferre S, Bouvier M, Fuxe K, Ciruela F, Lluís C, Franco R (2004) Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. *J Neurochem* 88:726–734
48. Ciruela F, Ferre S, Casado V, Cortes A, Cunha RA, Lluís C, Franco R (2006) Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. *Cell Mol Life Sci* 63:2427–2431
49. Yoshioka K, Saitoh O, Nakata H (2001) Heteromeric association creates a P2Y-like adenosine receptor. *Proc Natl Acad Sci U S A* 98:7617–7622
50. Suzuki T, Namba K, Tsuga H, Nakata H (2006) Regulation of pharmacology by hetero-oligomerization between A1 adenosine receptor and P2Y2 receptor. *Biochem Biophys Res Commun* 351:559–565
51. Kara FM, Chitu V, Sloane J, Axelrod M, Fredholm BB, Stanley ER, Cronstein BN (2010) Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function. *FASEB J* 24:2325–2333
52. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA (2000) Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. *J Biol Chem* 275:4429–4434
53. Morrison RR, Talukder MA, Ledent C, Mustafa SJ (2002) Cardiac effects of adenosine in A(2A) receptor knockout hearts: uncovering A(2B) receptors. *Am J Physiol Heart Circ Physiol* 282:H437–H444
54. Ramanathan M, Pinhal-Enfield G, Hao I, Leibovich SJ (2007) Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. *Mol Biol Cell* 18:14–23
55. Ernens I, Leonard F, Vausort M, Rolland-Turner M, Devaux Y, Wagner DR (2010) Adenosine up-regulates vascular endothelial growth factor in human macrophages. *Biochem Biophys Res Commun* 392:351–356
56. Burnstock G (2007) Physiology and pathophysiology of purinergic neurotransmission. *Physiol Rev* 87:659–797